^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KO-2806

    i
    Other names: KO-2806
    Associations

    News

    Trials
    Company:
    Kura Oncology
    Drug class:
    Farnesyl transferase inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    FIT-001: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=270, Recruiting, Kura Oncology, Inc.
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • HRAS mutation • HRAS overexpression
    |
    Cabometyx (cabozantinib tablet) • KO-2806
    7ms
    FIT-001: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=270, Recruiting, Kura Oncology, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • HRAS mutation • HRAS overexpression
    |
    Cabometyx (cabozantinib tablet) • KO-2806
    8ms
    The next generation farnesyltransferase inhibitor, KO-2806, blocks oncogenic signaling at multiple nodes to enhance the antitumor efficacy of KRASG12C inhibitor adagrasib in KRASG12C non-small cell lung carcinoma. (AACR-NCI-EORTC 2023)
    No abstract available
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Krazati (adagrasib) • KO-2806
    8ms
    FIT-001: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=270, Not yet recruiting, Kura Oncology, Inc.
    New P1 trial • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • HRAS mutation • HRAS overexpression
    |
    Cabometyx (cabozantinib tablet) • KO-2806